newsfilter
← Latest News
GlobeNewswire·

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discussions with the FDA to support resolution of the